GCTK Prices Fresh Cash, Not Equity Repair

Summary: Conditional Short Note. Glucotrack closed at $0.4715 on August 6, 2026, after a 55.55 million-share August 4 session and a 21.2% decline from that day's $0.5986 close. The August 4 filings disclose a $3.5 million senior secured bridge follow-on, a $2.0 million interim PIPE, and a three-year equity line with up to $50 million of purchase capacity. The bridge conversion, bridge warrants, and ELOC issuance above Nasdaq's exchange cap require stockholder approval. The PIPE's pre-funded and common warrants are issued, but their resale and the post-financing cash balance are not yet independently reconciled. This is a potential-supply and funding-pressure setup, not immediate float and not an executable short.

Research timestamp: 2026-08-07 16:03:58 Asia/Singapore (UTC+08:00). The latest Nasdaq historical record available in this run is the August 6 regular-session close. Nasdaq's quote endpoint returned no live last-sale fields during this pre-market check. Bid, ask, depth, borrow, short interest, options, dealer flow, fund flow, and exit-liquidity data were not verified.

Why This Is the Best Opportunity Right Now

The strongest counterargument is that the market has already done much of the work. GCTK is below the $0.75 per-share purchase price for the August 4 pre-funded warrants, the stockholder approval date is blank in the preliminary proxy, and the new bridge securities cannot convert or be exercised until approval. The $50 million ELOC is a right, not a draw. Glucotrack also reported $3.5 million of bridge follow-on proceeds and a $2.0 million PIPE, which can extend the company's life and create a squeeze before any new shares reach the market. A clinical or commercial CBGM update could overwhelm financing arithmetic.

GCTK still ranks first in this U.S.-only screen because the filings connect three separate pressure channels to a weak cash base: approval-gated bridge conversion, an approval-gated variable-price ELOC, and immediately exercisable PIPE warrants. The latest 10-Q reported $3.929 million of cash, $4.048 million of operating cash use for the three months ended March 31, a $156.172 million accumulated deficit, and substantial doubt about going concern. The August 4 financing is real capital, but the next cash and share-count filing has not yet shown whether it repaired the equity claim or only bought time.

The disagreement is not that every warrant will be exercised. It is that a price below the latest financing reference can still leave a highly reflexive capital structure: approval can unlock senior conversion and a variable-price funding line, while registration can turn the already issued PIPE claims into a resale event. The clean thesis is conditional on those gates opening and actual shares or cash being observed.

U.S.-only opportunity ranking

The user explicitly scoped this run to U.S. market short opportunities. The August 2026 target folder and the repository-wide article scan found no prior GCTK article or materially identical GCTK thesis. Recent ANY, BBAI, CYAB, FUSE, and FTCI financing shorts were excluded as duplicates or stale mechanisms.

Rank	Candidate	Latest reference and move	Why it made the screen	Why it lost or won	Screen score
1	GCTK	$0.4715, August 6 close; -21.2% from August 4 close; 55.55M August 4 volume	August 4 bridge follow-on, interim PIPE, preliminary proxy, and $50M ELOC; latest 10-Q shows cash pressure	Best combination of fresh filing evidence, approval catalyst, multiple financing mechanisms, and a dated next share-count/cash test. Borrow and resale evidence are missing.	35/40
2	TARS	$65.33, August 6 close; 16.7% above a $56 PIPE price; 1.65M volume	August 6 release disclosed a $125M PIPE expected to close August 7	More tradeable tape and a clean price gap, but strategic investors, unregistered shares, and clinical success make the offering price a weak ceiling.	31/40
3	SILO	$4.67, August 6 close; 78,298 volume	August 6 424B3 registers 1.906M shares against 1.253M common shares in the latest resale disclosure	Potential supply is large, but only part is immediately exercisable and the latest 10-Q says liquidity should cover at least twelve months. Thin volume weakens the expression.	30/40
4	SBFM	$1.40, August 6 close; 2.41M volume on August 4	August 3 8-K reset Series B warrants to $1.2202 after ATM sales; the latest 10-Q shows continuing ELOC activity	Fresh warrant reset is interesting, but the latest balance sheet is from March, the denominator has changed since then, and no new resale or cash reconciliation was found.	28/40

Vivos Therapeutics and SUI Group were useful rejects. Vivos had approximately $10.1 million of cash as of August 3 and traded below its $0.85 warrant financing price. SUI Group's reported token holdings were roughly equal to or greater than its equity value at the August 3 reference, creating a material treasury-value squeeze path. Neither was a clean short after the counterargument was priced.

Why This Can Jump Or Dump More Than 5% Soon

GCTK moved from an August 4 high of $0.7830 to a $0.3999 low and closed at $0.5986 on 55,550,380 shares. It closed at $0.4715 on August 6, with a $0.4329 to $0.5200 range and 1,755,197 shares. A further move of more than 5% is plausible because the tape is small relative to the potential financing claims, the August 4 event attracted unusually large volume, and no reliable spread or depth record was available.

The short-side trigger would be a verified approval, resale registration, actual exercise or resale, or post-financing share-count and cash filing followed by failed continuation. The squeeze trigger is the reverse: the company secures non-dilutive capital, reports a credible CBGM milestone, receives approval without visible supply, or experiences a borrow recall while the stock is near the $0.25 52-week low. The direction is uncertain until the market-structure gates and the financing state are observed.

Evidence quality is high for the financing and balance-sheet terms, medium for the price path, and low for external positioning. The exact closes and volumes are from Nasdaq's historical endpoint. Live borrow, short interest, options positioning, dealer flow, fund flow, spread, depth, and exit liquidity remain unknown.

What Should Surprise the Reader

The surprise is not the existence of another small-company financing. It is the number of distinct capital states that sit behind a $0.4715 common share price:

The company reported a $3.5 million senior secured bridge follow-on with a $4.487 million face amount, a 22% original issue discount, and a maturity nine months from July 14, 2026.
The follow-on notes cannot convert and the follow-on bridge warrants cannot be exercised until stockholder approval under Nasdaq Listing Rule 5635(d). If approved, the notes convert at the lower of Nasdaq's Minimum Price and 80% of the lowest daily VWAP over the prior fifteen trading days, subject to a floor equal to 20% of the Nasdaq Minimum Price.
The August 4 interim PIPE issued 2.666667 million pre-funded warrants at a $0.75 purchase price less a $0.0001 exercise price and 2.666667 million common warrants at a $1.50 exercise price. Both warrant series were issued with a 4.99% or elected 9.99% beneficial-ownership limitation. Issuance is not the same as exercise, resale, or current float.
The ELOC gives Glucotrack the right, not the obligation, to require up to $50 million of common-stock purchases over three years after a resale registration becomes effective. The company states in its preliminary proxy that it had not issued Purchase Shares under the ELOC as of that filing. It also agreed to $1 million of commitment shares and a commitment warrant with up to $10 million of aggregate value.

At the latest filed common denominator of 6.259 million shares, the 2.666667 million pre-funded warrant shares alone equal about 42.6% of the denominator. The full 5.333334 million interim PIPE warrant claims equal about 85.2% if every claim is exercised, ignoring ownership limits and later dilution. That is a stress ratio, not a share-count forecast. The ELOC's full capacity would imply approximately 106 million shares at $0.4715, but that arithmetic is only a capacity stress case because registration, purchase notices, volume limits, ownership caps, and cash needs govern the actual outcome.

The Setup

Glucotrack is developing a continuous blood-glucose monitoring product. The latest filed operating and balance-sheet data is for March 31, 2026, with the 10-Q filed May 14. It reported:

Item	Amount	Interpretation
Cash and cash equivalents, March 31	$3.929M	Pre-August financing cash; the post-financing balance is not yet filed.
Net cash used in operating activities, Q1	$4.048M	A large quarterly cash requirement relative to the pre-financing cash balance.
Net loss, Q1	$4.334M	Losses and cash use remain distinct, but both indicate funding pressure.
Accumulated deficit, March 31	$156.172M	Historical deficit, not an equity valuation target.
Common shares outstanding, May 14	6.259M	Latest filed denominator; August financing activity may have changed it.
Going-concern language	Substantial doubt	The company says it depends on external financing and cannot assure continued operations from revenue or financing.

The latest cash-to-quarterly-operating-use ratio is about 0.97 before considering financing receipts, restricted cash, subsequent spending, or other sources. It is not a runway date. The August 4 bridge and PIPE are reported financings, but no later balance sheet has yet reconciled cash received, fees, warrant exercise, or common shares outstanding.

The Market Price

Measure	Nasdaq historical record	Evidence boundary
August 6 last sale	$0.4715	Dated regular-session reference, accessed August 7 Singapore time.
August 6 high / low	$0.5200 / $0.4329	The low is not a short entry.
August 6 volume	1,755,197	Historical daily volume, not a depth or exit-liquidity measure.
August 5 close	$0.5250	The stock remained below the $0.75 pre-funded warrant purchase price.
August 4 close	$0.5986	Down 21.2% to August 6; the August 4 session traded 55,550,380 shares.
August 4 high / low	$0.7830 / $0.3999	Large range around the financing disclosure.
52-week range	$0.2500 to $14.14	The distance to the low makes squeeze and borrow risk material.
Filed-share reference value	About $2.95M	6.259M latest filed shares multiplied by $0.4715; current shares may differ.
Bid / ask / depth	Not available	No NBBO, order-book, venue, or exit-liquidity verification.

The price is a reference level, not an executable entry. A move from $0.4715 to the base target of $0.35 would be a 25.8% gross short return before borrow, fees, slippage, taxes, and gap risk. A move to $0.80 would be a 69.7% loss on the same price basis. The $0.75 PIPE price is a financing reference, not a floor or ceiling.

The Positioning

The filings support structural potential supply and funding urgency. They do not support a claim about current short crowding or holder selling. No live short-interest percentage, locate, borrow cost, recall terms, options chain, dealer gamma, fund flow, confirmed resale, or order-book depth was verified.

Capital state	Filed or contractual amount	What it proves and does not prove
Common shares outstanding	6.259M as of May 14	Latest filed denominator. It predates the August 4 financing and must not be treated as current without a later filing.
Existing bridge financing	Approximately $4.45M gross	Senior secured notes and warrants exist. The conversion and exercise claims remain subject to the documented approval and registration conditions.
Follow-on bridge	$3.5M principal; $4.487M face	New senior secured debt with a 22% original issue discount, 8% interest, nine-month maturity from July 14, and an 18% default rate on unpaid amounts after an event of default.
Follow-on bridge conversion	Variable, approval-gated	Lower of Nasdaq Minimum Price or 80% of the lowest fifteen-day daily VWAP, with a 20%-of-Minimum-Price floor. It is not current common stock.
Follow-on bridge warrants	125% of principal divided by the exercise price	Approval-gated five-year claims. The exercise price uses a $35M valuation formula and a floor, so the final share count is not fixed by the current quote.
Interim PIPE pre-funded warrants	2.666667M shares at $0.75 less $0.0001 exercise	Issued claims that are exercisable after issuance, subject to ownership limits. Exercise and resale are not verified.
Interim PIPE common warrants	2.666667M shares at $1.50	Immediately exercisable five-year claims, subject to a floor and ownership limits. They are out of the money at the August 6 close.
ELOC purchase capacity	Up to $50M over three years	A contractual funding option after resale registration and purchase notices, not a completed raise or immediate float. No Purchase Shares had been issued as of the preliminary proxy.
ELOC commitment package	$1M commitment shares and up to $10M commitment warrant value	Potential additional claims. Commitment shares are tied to resale-registration effectiveness and the warrant is subject to issuance and volume limits.
Actual post-financing common count and cash	Not yet filed	The most important missing bridge. Do not add potential claims to a later share count if they are already reflected there.

Positioning score: 3/5. The structural financing evidence is strong, but the external positioning evidence is absent. The short remains fail-closed until a locate, borrow, same-session liquidity, and exit plan are independently verified.

The Catalyst

The catalyst path is a sequence rather than a single headline:

Stockholder approval: The preliminary proxy seeks approval for the ELOC issuance and the bridge financing issuance. The special-meeting date and record date fields are blank in the document available in this run. Approval would remove the Nasdaq exchange-cap barrier for the specified claims. Failure to approve would not erase the existing financing documents, and the proxy describes additional meeting and liquidated-damages consequences.
Resale registration: For the interim PIPE, the company agreed to file a registration statement covering the pre-funded and common warrant shares on or before the thirtieth calendar day after the registration-rights agreement. It agreed to use commercially reasonable efforts to obtain effectiveness by the sixtieth day, or the ninetieth day if the SEC conducts a full review. Filing or effectiveness is a catalyst gate, not proof of resale.
First ELOC purchase: After the resale registration is effective, Glucotrack may issue purchase notices. The first settled purchase, shares delivered, purchase price, fees, and cash receipt are the adjudicating evidence. Capacity alone is not a draw.
Next share-count and cash filing: This should reconcile the August 4 bridge and PIPE, cash, fees, outstanding shares, warrant exercises, operating burn, and any registration or resale activity. It is the cheapest disconfirming test.
Maturity pressure: The follow-on bridge notes mature nine months from July 14, 2026, approximately April 14, 2027, subject to the full note terms. A maturity is funding pressure, not proof of an imminent default or equity issuance.

The cleanest disconfirming sequence is therefore stockholder approval or rejection, registration filing or effectiveness, actual exercise or resale, and the next cash/share-count filing. If the sequence shows cash retained, no meaningful issuance, and credible CBGM progress, the short thesis should be abandoned.

The Gap

The high-confidence observation is a capital-structure gap: the latest filed common denominator is 6.259 million shares, while the August 4 filings add $5.5 million of reported gross financing, 5.333 million interim PIPE warrant claims, approval-dependent bridge claims, and a $50 million ELOC option. The high-confidence inference is that the common equity can remain fragile if approval and registration unlock claims before operating cash conversion improves.

The lower-confidence part is timing. GCTK is already below the $0.75 pre-funded warrant purchase price, and the bridge and ELOC approvals are not yet effective. The market may have priced the overhang, the company may use the new capital to reach a value-creating clinical milestone, or a low-float squeeze may precede any resale. Calling the whole financing stack immediate float would be false precision.

The Payoff Map

The targets below are analytical price scenarios, not promises or personalized financial advice. “Gross short return” is calculated as (reference price - target price) / reference price, using the $0.4715 Nasdaq reference.

Scenario	Target price	Probability	Gross short return	What must be true
Top case for the short	$0.25	30%	+47.0%	Approval or registration opens the supply path, actual shares or cash pressure appear, and no non-dilutive operating rescue changes the denominator.
Base case	$0.35	45%	+25.8%	The financing stack remains an overhang, the next filing does not show durable cash conversion, and the stock revisits the recent low without a sustained squeeze.
Bottom case for the short	$0.80	25%	-69.7%	Fresh cash funds a credible CBGM milestone, approval is delayed without supply, non-dilutive capital arrives, or borrow and low-float dynamics overwhelm the financing thesis.

Probabilities sum to 100%. The probability-weighted price-only gross return is approximately +8.3% before borrow, fees, slippage, taxes, gap risk, and position-size limits. Executable EV cannot be computed because locate, borrow, spread, depth, and exit liquidity are unverified. That missing information is not a footnote. It is the variable that determines whether the modeled edge can be captured.

Price Target and Probability Map

The base target is $0.35, with an extension target of $0.25 and a price-risk level of $0.80. The $0.80 level is a review and risk-control threshold, not a claim that price alone proves the financing thesis wrong. Abandon the short thesis if a sustained reclaim above $0.80 is supported by a reconciled cash balance, credible CBGM or strategic evidence, delayed or failed supply catalysts, or a clean post-financing share count.

The price-only map has positive nominal EV, but the executable map is unknown. A borrow recall, halt, wide spread, shallow depth, or overnight gap can consume more than the modeled return. The correct current signal is research edge pending execution proof.

What Could Go Wrong

GCTK has already fallen 21.2% from the August 4 close and traded near its 52-week low. Shorting after a large decline can lose to a reflexive bounce even when the financing analysis is correct.
The $0.75 pre-funded warrant purchase price and $1.50 common-warrant exercise price are not floors. The stock is already below $0.75, and warrant holders may have no reason to sell or exercise immediately.
The reported $5.5 million of August 4 financing can extend the runway and give management time to produce a clinical, regulatory, partnership, or strategic catalyst.
Stockholder approval may be delayed or rejected. If approval fails, bridge and warrant terms remain binding but the expected timing and share path change, and the company may pursue another financing.
The ELOC is a right, not a draw. Treating the $50 million headline as immediate float would overstate the short thesis; treating it as unusable before registration and approval would also be wrong.
A registration statement can become effective without a holder selling. Actual resale, exercise, price, and proceeds must be observed.
A borrow recall, trading halt, low-float squeeze, or unavailable exit liquidity can turn a correct fundamental view into an unmanageable position.
The August 4 volume spike is evidence of price discovery and attention, not evidence of short interest, dealer positioning, or confirmed holder supply.

What Would Prove This Wrong

The capital-structure thesis is wrong, or not yet actionable, if any of the following occurs:

A subsequent filing shows a reconciled cash balance, lower operating burn, no material common increase, and a credible path to fund CBGM development without another equity draw.
The company secures non-dilutive capital, a partnership, or an operating milestone that changes expected cash generation before approval or resale catalysts open.
Stockholder approval is delayed or rejected and the company demonstrates it can meet obligations without issuing common stock or drawing the ELOC.
GCTK reclaims $0.80 for three regular sessions on verified volume while the financing and share-count filings show no meaningful new supply and the operating evidence improves. This is a risk-control rule, not an intrinsic-value claim.
A responsible locate and borrow cannot be obtained at acceptable cost and recall terms. That does not falsify the capital-structure thesis, but it falsifies the trade expression.

Best Trade Strategy

Direction: Conditional short bias, research only.

Preferred instrument: GCTK common stock only after all execution gates pass. No options expression is recommended because a live options chain, spread, open interest, implied volatility, and exit liquidity were not verified.

Common-stock stance: Watchlist. entry.price = null; execution.can_execute = false.

Entry reference: $0.4715, the August 6 Nasdaq historical close. A permissible research trigger would require a verified locate and borrow, a fresh regular-session quote, acceptable spread and depth, sufficient volume and exit liquidity, then failed continuation after approval, registration, actual exercise or resale, or a reconciled cash/share-count catalyst. A staged review around a rebound into the $0.55 to $0.65 area could be considered only if those conditions are met. Do not short the $0.4329 intraday low or any fresh halt-driven print.

Targets and invalidation: Base target $0.35, extension target $0.25, price-risk level $0.80, with fundamental review at every filing. Do not hold mechanically to the April 2027 maturity.

Timeline: The first 2 to 8 weeks are the highest-value catalyst window for the proxy, registration, first exercise or resale, and the next cash/share-count update. The bridge maturity is a longer funding-pressure date, not a reason to hold a short without borrow and liquidity confirmation.

Do not trade if:

No locate, borrow availability, borrow cost, recall terms, or settlement capacity is verified.
The quote, spread, depth, venue status, volume, or exit liquidity is missing or abnormal.
The stock is making a fresh intraday low without a failed bounce.
The only evidence is the ELOC capacity, registered potential supply, the $0.75 financing reference, or the August 4 volume spike.
A material CBGM milestone, non-dilutive financing, strategic transaction, or cash receipt creates an unfailed squeeze path.
Stockholder approval, registration, actual exercise, resale, or post-financing share count is assumed rather than documented.
Options or leveraged expression is considered without a verified live chain and open interest.

Monitoring checklist:

Check	Required evidence	Current state
Approval	Special-meeting date, vote result, and scope of ELOC and bridge approval	Preliminary proxy filed; date and vote unverified
Registration	PIPE resale filing, effectiveness, and any bridge resale registration	Not verified in this run
Supply	Actual pre-funded exercise, common-warrant exercise, bridge conversion, ELOC purchase, or resale	Not verified
Cash	Post-August cash balance, financing fees, operating burn, and liquidity	Not yet reconciled in a later filing
Operations	CBGM milestone, regulatory or clinical update, revenue, and operating cash flow	Latest Q1 cash evidence is weak; next update pending
Market structure	NBBO, depth, venue, locate, borrow, short interest, options, dealer and fund flow	Unverified
Invalidation	$0.80 reclaim supported by cash, operating progress, or absence of supply	Not triggered in this research pass

Bottom Line

GCTK is the best current U.S.-only short candidate because the fresh filings expose a specific disagreement between a small filed denominator, approval-gated senior claims, an unissued ELOC capacity, and a weak pre-financing cash position. The short is not “the $50 million ELOC will become float.” The claim is that approval, registration, and actual draw or resale can create a closing mechanism while the company still needs capital.

The counterargument is equally specific. The stock is already below the latest pre-funded purchase price, the proxy does not yet schedule the vote, the company received reported financing proceeds, and a CBGM or non-dilutive funding surprise can generate a violent rebound. Potential supply is not immediate float, and live borrow is unknown.

Publish decision: Conditional Short Note. The evidence supports a monitorable financing-pressure thesis. It does not support an executable trade today.

Research Quality Scorecard

Criterion	Score	Reason
Is the mispricing specific?	5/5	The thesis separates cash, senior bridge claims, approval, ELOC capacity, PIPE warrants, registration, and actual supply.
Is there evidence beyond narrative?	4/5	Fresh SEC filings and dated Nasdaq prices support the structure; post-financing cash and share count remain pending.
Is positioning supported or clearly labeled as uncertain?	3/5	Structural claims are sourced, but live borrow, short interest, options, dealer flow, fund flow, and holder selling are missing.
Is there a catalyst or plausible closing mechanism?	5/5	Approval, registration, first ELOC purchase, exercise or resale, and the next cash/share-count filing are observable.
Is the downside case described honestly?	4/5	Cash rescue, CBGM progress, delayed approval, and squeeze risks are explicit, but the equity is highly path-dependent.
Is the strongest counterargument included?	5/5	The below-financing price, fresh cash, absent meeting date, and out-of-the-money warrants are treated as central evidence against a simple short.
Is the article useful even if the trade is not taken?	5/5	The denominator bridge and catalyst sequence are reusable for approval-gated ELOC and bridge financings.
Are all factual claims sourced or marked as unverified?	4/5	SEC and Nasdaq claims are sourced; future cash, approval, resale, and market-structure states are explicitly marked unknown.
Total	35/40	Conditional Short Note, not an executable trade.

Section 17 Gate

Gate	Status
Specific mispricing, evidence beyond narrative, uncertain positioning, catalyst, honest downside, strongest counterargument, and reader utility	Yes, addressed in the article and scorecard
No hype; headline matches evidence; best opportunity explained	Yes
More-than-5% move path includes direction, trigger, timeframe, and evidence quality	Yes
Sophisticated-reader surprise identified	Yes
Top, base, and bottom targets with probabilities totaling 100%	Yes, 30% / 45% / 25%
Dedicated Research Quality Scorecard	Yes
All reader-facing tables remain Markdown	Yes
Optional table images	N/A, none requested
Inline illustration prompt with The Mispricing Desk watermark requirement	Yes
Best Trade Strategy with instrument, stance, TP, invalidation, timeline, risks, no-trade rules, monitoring, and price-data gaps	Yes
Technical signals are not the sole thesis	Yes, no technical indicator is used as the thesis
Geography lane	N/A by explicit user request for U.S. opportunities only
Japan small-cap price rule	N/A by explicit U.S.-only scope
Live Substack finish	N/A, not requested

Sources

Glucotrack August 4, 2026 Form 8-K, follow-on bridge and interim PIPE (primary)
Glucotrack preliminary proxy statement for the special meeting (primary)
Glucotrack March 31, 2026 Form 10-Q (primary)
GCTK Nasdaq historical daily data, August 1 to August 7, 2026 (market data, accessed 2026-08-07 Singapore time)
Tarsus Pharmaceuticals August 6, 2026 PIPE release and TARS Nasdaq historical daily data (screened candidate evidence)
Silo Pharma August 6, 2026 Form 424B3, Silo Pharma March 31, 2026 Form 10-Q, and SILO Nasdaq historical daily data (screened candidate evidence)
Sunshine Biopharma August 3, 2026 Form 8-K, Sunshine Biopharma March 31, 2026 Form 10-Q, and SBFM Nasdaq historical daily data (screened candidate evidence)

AI Illustration Prompt

Create a restrained, high-end editorial financial illustration for The Mispricing Desk about a small medical-device issuer whose fresh cash has not repaired its equity structure. Place a dark glass laboratory tower on a forensic balance-sheet table. Surround it with three transparent layers: a senior secured bridge note marked approval gate, a pre-funded warrant card marked $0.75, and a variable-price equity line marked $50M capacity, with the last label visibly separated from a smaller empty cash-receipt box. Add a thin red thread running through a blank stockholder-meeting calendar, a registration-statement folder, and a common-share denominator card. In the background, show a sharp price line falling from a crowded financing spike, with a single upward spark to communicate squeeze risk. Use graphite, ink blue, muted copper, ivory paper, and one warning-red accent. No real company logos, no trading rockets, no meme imagery, no candlestick clutter, no personalized financial advice. Include a subtle but clear watermark reading The Mispricing Desk.